CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 130 enrolled
Drug / intervention
olanzapine +1 moredrug
Likely dose
Olanzapine 5-20 mg orally daily or Risperidone 2-6 mg orally twice dailyAI-extracted
Key inclusion· 3
  • ✓Age 18-65 years
  • ✓Diagnosed with Schizophrenia or Schizoaffective Disorder
  • ✓Able to attend scheduled office visits
Key exclusion· 5
  • ✕Pregnant or breastfeeding
  • ✕BMI greater than 40
  • ✕Diabetes, heart disease, or other unstable illness
  • ✕Known HIV positive

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00190749
NCT00190749Phase 4Completed
CompareCT.gov

Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone

Eli Lilly and Company·interventional·Posted Sep 19, 2005·Updated May 4, 2010

In Brief

A Phase 4 clinical trial evaluating olanzapine and risperidone for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 130 participants across 1 site.

Detailed Summary

This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2005
Enrollment StartOct 1, 2003
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 20.8 years ago

Interventions

olanzapinedrug

5-20 mg, oral, capsules, daily, 12 weeks.

risperidonedrug

2-6 mg, oral, capsules, twice daily (BID), 12 weeks.